New Lung Cancer Drug Shows Promise in Early Trial
Patients with metastatic lung cancer saw a 56% response rate in a preliminary study of the experimental drug FMC-376.
Updated on Oct. 25, 2026 in Cancer
A Phase 1 trial of the investigational drug FMC-376 shows a 56% objective response rate in patients with metastatic non-small cell lung cancer. These results highlight a potential new treatment path for patients who have already undergone chemotherapy and immunotherapy.
Why it matters
For patients with advanced lung cancer whose disease has progressed despite standard chemotherapy and immunotherapy, these preliminary results offer an early indication of a potential new treatment option. The findings represent a key initial step in evaluating the efficacy of this therapy for refractory cases.
Data from the Phase 1A monotherapy portion of the PROSPER trial showed a 56% objective response rate, with 10 of 18 evaluable patients responding to the treatment. Because this is a preliminary Phase 1 trial, these findings are considered early-stage.
The players
Frontier Medicines
A biotechnology company focused on developing precision medicines and targeted therapies for challenging diseases including cancer.
The details
FMC-376 is an investigational agent administered orally at a dose of 500 milligrams twice daily. The drug is currently being tested in patients who have already received prior chemotherapy and immunotherapy, targeting metastatic non-small cell lung cancer that has persisted or returned following these initial standard interventions.
Timeline
- 2026-10-25
European Society for Medical Oncology Congress held in Madrid.
Health Landscape
The study sits within the broader PROSPER trial, which aims to address treatment resistance in advanced non-small cell lung cancer. This investigation reflects an ongoing push to find targeted options for patients who have exhausted traditional lines of systemic therapy.
This drug is currently in early clinical testing and is not yet available for general use. Patients managing metastatic non-small cell lung cancer should discuss current clinical trial opportunities and standard of care developments with their oncologist.
The takeaway
Early trial data indicate potential promise for FMC-376 in treating advanced lung cancer that has resisted previous therapies. Patients interested in emerging research should maintain an ongoing dialogue with their oncology team regarding eligibility for experimental treatment protocols.
Further reading
For more information on the latest research and standard care protocols, visit Cancer.
